JSC “Grindeks” informs that it has received approval from the government
agency
“Investment and Development Agency of Latvia” of allocation of the
co-financing
from the European Regional Development Fund for the construction
of UDCA
(ursodeoxycholic acid) manufacturing unit. Allocated amount of
co-financing is
2.8 million lats. 


About JSC “Grindeks”

“Grindeks” is
the leading pharmaceutical company in the Baltic States. The main
directions
of its operation are research, development, manufacturing and sales
of
original products, as well as generics and active pharmaceutical
ingredients.
“Grindeks” specializes in the heart and cardiovascular,
psychotropic and
anti-cancer therapeutic groups of medications. 

“Grindeks” concern consists
of four subsidiary companies in Latvia, Estonia and
Russia; as well as
representatives and representative offices in 14 countries.
Products of the
company are exported to more than 40 countries and its export
comprises more
than 96% of the total turnover. The main markets are the Baltic
States, Russia
and other CIS countries, as well as Japan and USA. The shares of
JSC
„Grindeks” are listed in the Official List of “NASDAQ OMX Riga”. 


Further
information:
Laila Kļaviņa
Head of the Communications Department
JSC
“Grindeks”
E-mail: laila.klavina@grindeks.lv
Phones: +371 67083370, +371
29256012